Overview

Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial

Status:
Completed
Trial end date:
2021-12-16
Target enrollment:
Participant gender:
Summary
QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection, is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adults' patients with primary chronic ITP during a 24-week treatment period.
Phase:
Phase 3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.